Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2023 Jan 24:44:44.
doi: 10.11604/pamj.2023.44.44.38646. eCollection 2023.

Ustekinumab-induced autoimmune hepatitis: a case report

Ali Said Samah  1 , Tennenbaum Ruth  1 , Kallel Roua  1 , Vitte René Louis  1
Affiliations
Case Reports

Ustekinumab-induced autoimmune hepatitis: a case report

Ali Said Samah et al. Pan Afr Med J. .

Abstract

Ustekinumab is a fully human monoclonal antibody that binds to interleukin (IL)-12/23. Ustekinumab-related liver injury (UST) is rare. There is limited data available on the potential for ustekinumab-liver interaction. We report the case of a patient from our institution followed for colitis ulcerative who developed autoimmune hepatitis (AIH) during treatment with ustekinumab. The diagnosis of autoimmune hepatitis was retained on the simplified criteria for autoimmune hepatitis. Therapeutic management consisted of stopping ustekinumab and starting corticosteroids and immunosuppressants, with regression of cytolysis at 2 months. The purpose of the article is to alert readers and encourage them to report similar cases for better knowledge of the drug.

Keywords: Ustekinumab; autoimmune hepatitis; case report; drug-induced hepatitis.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interests.

Figures

Figure 1
Figure 1
A) polymorphic infiltrate essentially lymphoplasmacytic moderate portal with the presence of a few rare eosinophilic polynuclears; B) lesions of patchy necrosis
See this image and copyright information in PMC

References

    1. Ghabril M, Bonkovsky HL, Kum C, Davern T, Hayashi PH, Kleiner DE, et al. Liver injury from tumor necrosis factor-α antagonists: analysis of thirty-four cases. Clin Gastroenterol Hepatol. 2013 May;11(5):558–564.e3. - PMC - PubMed
    1. Alexandre Jenkins, Amy Austin, Catherine Hugues, Brett Sadowski, Aube Torres. Autoimmune hepatitis induced by infliximab. BMJ Case Report. 2021 May;14:5.
    1. Ruiz Salas V, Puig L, Alomar A. Ustekinumab in clinical practice: response depends on dose and prior therapy. J Eur Acad Dermatol Venereol. 2012 Apr;26(4):508–13. - PubMed
    1. Llamas-Velasco M, Concha-Garzón MJ, García-Diez A, Daudén E. Liver Injury in Psoriasis Patients Receiving Ustekinumab: a retrospective study of 44 patients treated in the clinical practice setting. Actas Dermosifiliog. 2015 Jul-Aug;106(6):470–6. - PubMed
    1. Leonardi CL, Kimball AB, Papp KA, Yeilding N, Guzzo C, Wang Y, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: results at 76 weeks from a randomized, double-blind, placebo-controlled trial (PHOENIX 1) Lancet. 2008 May 17;371(9625):1665–74. - PubMed

Publication types

MeSH terms